A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Approximately 36 HIV-negative women, aged >18 and < 50, will be enrolled in this study. Each
volunteer will have a 2:1 chance of receiving dapivirine gel versus placebo. The volunteers
will receive investigational product for a total of 42 days.